Drug Overview
Alofisel (darvadstrocel; TiGenix/Takeda) is a suspension of allogeneic expanded adipose-derived stem cells via intralesional injection.
The therapy is being developed in Crohn’s disease for the treatment of complex perianal fistulas which show an inadequate response to at least one conventional or biologic therapy, including antibiotics, immunosuppressants, or anti-tumor necrosis factor (TNF) agents.
Alofisel (darvadstrocel; TiGenix/Takeda) is a suspension of allogeneic expanded adipose-derived stem cells via intralesional injection.
The therapy is being developed in Crohn’s disease for the treatment of complex perianal fistulas which show an inadequate response to at least one conventional or biologic therapy, including antibiotics, immunosuppressants, or anti-tumor necrosis factor (TNF) agents.
Table of Contents
OVERVIEWDrug Overview
Product Profiles
Alofisel: Crohn's disease
LIST OF FIGURES
Figure 11: The authors drug assessment summary of Cimzia in Crohn’s disease
Figure 40: Top treatment challenges in Crohn’s disease
Figure 41: Summary of future usage of biosimilar infliximab at one year and three years post-launch
LIST OF TABLES
Table 1: Alofisel drug profile
Table 2: Alofisel Phase III data in Crohn’s disease
Table 3: Alofisel Phase III trial in Crohn’s disease
Table 4: Alofisel Phase I/II data in Crohn’s disease
Table 5: Alofisel sales for Crohn’s disease across the US, Japan, and five major EU markets, by country, 2016–25
